Puma Biotechnology (PBYI) 34.16 $PBYI
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 11.76 (-0.01), PFE: 36.24 (+0.09), PBYI: 34.16 (-0.33)
Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
BusinessWire - Thu Jul 07, 7:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in the July 7 issue of The New England Journal of Medicine.
PBYI: 34.16 (-0.33)
Puma (PBYI) Submits Neratinib Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 8:00AM CDT
Puma (PBYI) announced that it has submitted a Marketing Authorisation Application (MAA) in the EU for its lead pipeline candidate, neratinib.
PFE: 36.24 (+0.09), BMY: 76.20 (+0.81), PBYI: 34.16 (-0.33)
Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
BusinessWire - Mon Jun 27, 7:15AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib. The potential indication is for the extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with trastuzumab (Herceptin(R))-based adjuvant therapy. The submission is based upon the ExteNET Phase III study, which reached its primary endpoint whereby neratinib demonstrated a statistically significant reduction of risk of invasive disease recurrence or death versus placebo.
PBYI: 34.16 (-0.33)
PBYI August 5th Options Begin Trading
DividendChannel.com - Thu Jun 23, 9:43AM CDT
Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 5th expiration.
PBYI: 34.16 (-0.33)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.24 (+0.03), JAZZ: 142.26 (+2.10), GRFS: 16.95 (-0.13), PBYI: 34.16 (-0.33)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 55.73 (+0.35), AZN: 30.20 (+0.23), RTRX: 18.57 (+0.10), PBYI: 34.16 (-0.33)
Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 34.16 (-0.33)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.52 (unch), PBYI: 34.16 (-0.33)
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 34.16 (-0.33)
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 55.73 (+0.35), RTRX: 18.57 (+0.10), BMY: 76.20 (+0.81), PBYI: 34.16 (-0.33)
Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 34.16 (-0.33)
Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 34.16 (-0.33)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.81 (+0.30), INO: 9.08 (-0.04), VVUS: 1.15 (+0.01), TEVA: 52.46 (+1.53), ARNA: 1.62 (unch), PBYI: 34.16 (-0.33)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 31.32 (+0.70), JAZZ: 142.26 (+2.10), PBYI: 34.16 (-0.33)
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 34.16 (-0.33)
Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 34.16 (-0.33)
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 8:21AM CDT
Image source: Puma Biotechnology. What: Shares of Puma Biotechnology , a biopharmaceutical company dedicated to development of novel cancer therapies, fell 36.6% last month, according to data from S&P Global Market Intelligence . ...
PBYI: 34.16 (-0.33)
Why is Puma Biotech Stock (PBYI) Plummeting Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:04PM CDT
Puma Biotechnology is having a terrible day of trading. Why is that?
PBYI: 34.16 (-0.33)
Puma's (PBYI) Filing for Breast Cancer Drug Neratinib Delayed
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 10:20AM CDT
Puma Biotechnology (PBYI) announced that the regulatory filing for its breast cancer drug neratinib will be delayed until mid-2016.
AMAG: 25.50 (-0.02), ANIK: 53.19 (+0.40), PBYI: 34.16 (-0.33)
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 11.76 (-0.01), PFE: 36.24 (+0.09), PBYI: 34.16 (-0.33)
Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
BusinessWire - Thu Jul 07, 7:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in the July 7 issue of The New England Journal of Medicine.
PBYI: 34.16 (-0.33)
Puma (PBYI) Submits Neratinib Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 8:00AM CDT
Puma (PBYI) announced that it has submitted a Marketing Authorisation Application (MAA) in the EU for its lead pipeline candidate, neratinib.
PFE: 36.24 (+0.09), BMY: 76.20 (+0.81), PBYI: 34.16 (-0.33)
Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
BusinessWire - Mon Jun 27, 7:15AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib. The potential indication is for the extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with trastuzumab (Herceptin(R))-based adjuvant therapy. The submission is based upon the ExteNET Phase III study, which reached its primary endpoint whereby neratinib demonstrated a statistically significant reduction of risk of invasive disease recurrence or death versus placebo.
PBYI: 34.16 (-0.33)
PBYI August 5th Options Begin Trading
DividendChannel.com - Thu Jun 23, 9:43AM CDT
Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 5th expiration.
PBYI: 34.16 (-0.33)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.24 (+0.03), JAZZ: 142.26 (+2.10), GRFS: 16.95 (-0.13), PBYI: 34.16 (-0.33)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 55.73 (+0.35), AZN: 30.20 (+0.23), RTRX: 18.57 (+0.10), PBYI: 34.16 (-0.33)
Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 34.16 (-0.33)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.52 (unch), PBYI: 34.16 (-0.33)
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 34.16 (-0.33)
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 55.73 (+0.35), RTRX: 18.57 (+0.10), BMY: 76.20 (+0.81), PBYI: 34.16 (-0.33)
Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 34.16 (-0.33)
Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 34.16 (-0.33)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.81 (+0.30), INO: 9.08 (-0.04), VVUS: 1.15 (+0.01), TEVA: 52.46 (+1.53), ARNA: 1.62 (unch), PBYI: 34.16 (-0.33)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 31.32 (+0.70), JAZZ: 142.26 (+2.10), PBYI: 34.16 (-0.33)
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 34.16 (-0.33)
Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 34.16 (-0.33)
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 8:21AM CDT
Image source: Puma Biotechnology. What: Shares of Puma Biotechnology , a biopharmaceutical company dedicated to development of novel cancer therapies, fell 36.6% last month, according to data from S&P Global Market Intelligence . ...
PBYI: 34.16 (-0.33)
Why is Puma Biotech Stock (PBYI) Plummeting Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:04PM CDT
Puma Biotechnology is having a terrible day of trading. Why is that?
PBYI: 34.16 (-0.33)
Puma's (PBYI) Filing for Breast Cancer Drug Neratinib Delayed
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 10:20AM CDT
Puma Biotechnology (PBYI) announced that the regulatory filing for its breast cancer drug neratinib will be delayed until mid-2016.
AMAG: 25.50 (-0.02), ANIK: 53.19 (+0.40), PBYI: 34.16 (-0.33)
